Combination of lipitor and celebrex inhibits prostate cancer VCaP cells in vitro and in vivo

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3357-3363

  Huang, Huarong ^a   Cui, Xiao Xing ^b   Chen, Shaohua ^c   Goodin, Susan ^d   Liu, Yue ^b   He, Yan ^a   Li, Dongli ^a   Wang, Hong ^b   Van Doren, Jeremiah ^b   Dipaola, Robert S ^d   Conney, Allan H ^a,d   Zheng, Xi ^a,b  

^a GUANGDONG UNIVERSITY OF TECHNOLOGY   (China)

^b RUTGERS UNIVERSITY   (United States)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

NF B; NSAIDs; Orthotopic; Prostate cancer; Statin

Indexed keywords

ATORVASTATIN; CELECOXIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; STATIN (PROTEIN); SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER INHIBITION; CASPASE ASSAY; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; CELL GROWTH; DRUG SCREENING; NFΚB; NSAIDS; ORTHOTOPIC; PATHOLOGY; PROSTATE TUMOR; SCID MOUSE; TUMOR CELL LINE;

NFΚB; NSAIDS; ORTHOTOPIC; PROSTATE CANCER; STATIN;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; HEPTANOIC ACIDS; HUMANS; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; PYRAZOLES; PYRROLES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906319022     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Stein MN, Goodin S and Dipaola RS: Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res 18: 1848-1854, 2012.
3. Seruga B and Tannock IF: Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol 29: 3686-3694, 2011.
4. Thomas BM, Smith C, Evans J, Button MR, Kumar S, Palaniappan N, Staffurth J, Tanguay JS and Lester JF: Time to prostate-specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. Med Oncol 30: 719-725, 2013.
5. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ and Calle EE: Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 16: 2213-2217, 2007.
6. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, Orav EJ, Seeger JD, Sadler MC, Quesenberry CP Jr., Sternfeld B, Jacobsen SJ, Whitmer RA and Caan BJ: Statin use and risk of prostate cancer in the California Men's Health Study Cohort. Cancer Epidemiol Biomarkers Prev 16: 2218-2225, 2007.
7. Murtola T, Tammela TLJ, Lahtela J and Auvinen A: Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 16: 2226-2232, 2007.
8. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC and Giovannucci E: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98: 1819-1825, 2006.
9. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL and Freedland SJ: Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 116: 3389-3398, 2010.
10. Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S and Azoulay L: Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 32: 5-11, 2014.
11. Wang C, Tao W, Wang Y, Bikow J, Lu B, Keating A, Verma S, Parker TG, Han R and Wen XY: Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur Urol 58: 418-426, 2010.
12. Park YH, Seo SY, Lee E, Ku JH, Kim HH and Kwak C: Simvastatin induces apoptosis in castrate resistant prostate cancer cells by deregulating nuclear factor-κB pathway. J Urol 189: 1547-1552, 2013.
13. Abedinpour P, Baron VT, Welsh J and Borgström P: Regression of prostate tumors upon combination of hormone ablation therapy and Celebrex in vivo. Prostate 71: 813-823, 2010.
14. Harris RE: Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17: 55-67, 2009.
15. Carles J, Font A, Mellado B, Domenech M, Gallardo E, González-Larriba JL, Catalan G, Alfaro J, Gonzalez Del Alba A, Nogué M, Lianes P and Tello JM: Weekly administration of docetaxel in combination with estramustine and Celebrex in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. Br J Cancer 97: 1206-1210, 2007.
16. Adhami VM, Malik A, Zaman N, Sarfaraz S, Siddiqui IA, Syed DN, Afaq F, Pasha FS, Saleem M and Mukhtar H: Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res Mar 13: 1611-1619, 2007.
17. Zheng X, Cui XX, Gao Z, Zhao Y, Lin Y, Shih WJ, Huang M-T, Liu Y, Rabson A, Reddy B, Yang CS and Conney AH: Lipitor and Celebrex in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res (Phila Pa) 3: 114-24, 2010.
18. Zheng X, Cui XX, Avila GE, Huang MT, Liu Y, Patel J, Kong AN, Paulino R, Shih WJ, Lin Y, Rabson AB, Reddy BS and Conney AH: Lipitor and Celebrex inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res 13: 5480-5487, 2007.
19. Wang H, Cui XX, Goodin S, Ding N, Van Doren J, Du Z, Huang MT, Liu Y, Cheng X, Dipaola RS, Conney AH and Zheng X: Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of Lipitor and Celebrex. Oncol Rep 31: 835-841, 2014.
20. Xiao W, Hodge DR, Wang L, Yang X, Zhang X and Farrar WL: NF-κB activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NFκB regulatory site in autocrine human multiple myeloma cells. Cancer Biol Ther 3: 1007-1017, 2004.
21. Ploszaj T, Motyl T, Orzechowski A, Zimowska W, Wareski P, Skierski J and Zwierzchowski L: Antiapoptotic action of prolactin is associated with up-regulation of Bcl2 and down-regulation of Bax in HC11 mouse mammary epithelial cells. Apoptosis 3: 295-304, 1998.
22. Zheng X, Chang RL, Cui XX, Avila GE, Lee S, Lu YP, Lou YR, Shih WJ, Lin Y, Reuhl K, Newmark H, Rabson A and Conney AH: Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice. Cancer Res 64: 1811-1820, 2004.
23. Wei X, Du ZY, Cui XX, Verano M, Mo RQ, Tang ZK, Conney AH, Zheng X and Zhang K: Effects of cyclohexanone analogues of curcumin on growth, apoptosis and NF-κB activity in PC-3 human prostate cancer cells. Oncol Lett 4: 279-284, 2012.
24. Zhou DY, Zhang K, Conney AH, Ding N, Cui XX, Wang H, Verano M, Zhao SQ, Fan YX, Zheng X and Du ZY: Synthesis and evaluation of curcumin-related compounds containing benzyl piperidone for their effects on human cancer cells. Chem Pharm Bull (Tokyo) 61: 1149-1155, 2013.
25. Jain G, Cronauer MV, Schrader M, Möller P and Marienfeld RB: NF-κB signaling in prostate cancer: a promising therapeutic target? World J Urol 30: 303-310, 2012.
26. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gélinas C and Rabson AB: Mechanisms of constitutive NF-κB activation in human prostate cancer cells. Prostate 52: 183-200, 2002.
27. Hoesel B and Schmid JA: The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 12: 86, 2013.
28. Rajasekhar VK, Studer L, Gerald W, Socci ND and Scher HI: Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling. Nat Commun 2: 162, 2011.
29. Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, Scher HI and Gerald WL: NF-κB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 175: 489-499, 2009.
30. Seo SI, Song SY, Kang MR, Kim MS, Oh JE, Kim YR, Lee JY, Yoo NJ and Lee SH: Immunohistochemical analysis of NF-κB signaling proteins IKKε, p50/p105, p52/ p100 and RelA in prostate cancers. APMIS 117: 623-628, 2009.
31. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE and Matusik RJ: The nuclear factor-κB pathway controls the progression of prostate cancer to androgenin-dependent growth. Cancer Res 68: 6762-6769, 2008.
32. Shimada K, Nakamura M, Ishida E, Kishi M, Matsuyoshi S and Konishi N: The molecular mechanism of sensitization to Fas-mediated apoptosis by 2-methoxyestradiol in PC3 prostate cancer cells. Mol Carcinog 39: 1-9, 2004.
33. Zheng X, Chang RL, Cui XX, Avila G, Huang MT, Liu Y, Kong AN, Rabson AB and Conney AH: Inhibition of NF-κB by(E)3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile (BAY11-7082; BAY) is associated with enhanced 12-O-tetradecanoylphorbol-13-acetate-induced growth suppression and apoptosis in human prostate cancer PC-3 cells. Int J Oncol 32: 257-264, 2008.
34. O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, Rani S, O'Driscoll L, Fitzpatrick JM and Watson RW: Characterisation and manipulation of docetaxel-resistant prostate cancer cell lines. Mol Cancer 10: 126, 2011.
35. Zheng X, Cui XX, Gao Z, Zhao Y, Shi Y, Huang MT, Liu Y, Wagner GC, Lin Y, Shih WJ, Rao CV, Yang CS and Conney AH: Inhibitory effect of dietary Lipitor and Celebrex together with voluntary running wheel exercise on the progression of androgen-dependent LNCaP prostate tumors to androgen independence. Exp Ther Med 2: 221-228, 2011.
36. Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ and Posvar EL: Multiple-dose pharmacokinetics, pharmacodynamics, and safety of Lipitor, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 60: 687-95, 1996.
37. Lennernäs H: Clinical pharmacokinetics of Lipitor. Clin Pharmacokinet 42: 1141-1160, 2003.
38. Davies NM, McLachlan AJ, Day RO and Williams KM: Clinical pharmacokinetics and pharmacodynamics of Celebrex: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38: 225-242, 2000.